Skip to main content
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. — Investor Relations & Filings

Ticker · PYXS ISIN · US7473241013 US Manufacturing
Open in API
Filings indexed 308 across all filing types
Latest filing 2021-11-15 Interim / Quarterly Rep…
Country US United States of America
Listing US PYXS

About Pyxis Oncology, Inc.

https://pyxisoncology.com/

Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers. The company's differentiated portfolio of clinical assets is centered on two primary modalities: antibody-drug conjugates (ADCs) and immuno-oncology (IO). Its ADC technology platform is designed to deliver potent cancer-killing agents directly to tumor cells for enhanced safety and efficacy. The immuno-oncology programs utilize monoclonal antibodies (mAbs) to mobilize the body's immune system to attack cancer cells by blocking tumor defense mechanisms and overcoming immune suppression. Pyxis Oncology is advancing its product candidates as both monotherapies and in combination with other therapies to improve outcomes for patients with solid tumors.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report 9M 2021
2021-11-15 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and references a press release announcing financial results for the third quarter and nine months ended September 30, 2021. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes a press release as an exhibit. The length is 3503 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document announcing financial results via a press release in a Form 8-K is best classified as an Earnings Release (ER).
2021-11-15 English
SC 13G
Major Shareholding Notification
2021-10-25 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Pyxis Oncology, Inc. It registers securities under the Securities Act of 1933 related to stock plans and employee stock purchase plans. The text includes details about the registration fee, incorporation by reference of other SEC filings, indemnification provisions for directors and officers, and other legal and corporate governance information. There are no financial statements, earnings data, or management discussion of financial results. The document is a registration statement for securities issuance, not a financial report, earnings release, or management report. It is not an announcement of a report but the actual registration filing. Form S-8 is a specific SEC registration form for securities to be offered to employees under stock plans. This type of filing is best classified under Regulatory Filings (RNS) as it is a regulatory compliance document that does not fit into other specific categories like capital updates or earnings releases.
2021-10-22 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-10-22 English
FORM 4
Director's Dealing
2021-10-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.